PLEASE CALL US FOR AN APPOINTMENT
We offer stem cell therapies for the following ophthalmological conditions and diseases:
Stem cell science has focused on developing protocols to mitigate the loss of vision that occurs in ophthalmologic conditions including Retinitis Pigmentosa, Macular Degeneration, Optic Neuritis, and Glaucoma. The properties of mesenchymal stem cells such as plasticity, neuroprotection, and immunomodulation possess many advantages to addressing ophthalmologic diseases.
Stem Cell Treatment for Macular Degeneration:
Age-related macular degeneration (AMD) is the most common retinal degenerative disease in the elderly. This devastating disease affects the macula, which is the part of the retina that allows people to read, visualize faces, and drive. Treatment options include antioxidant vitamins and laser therapy; however, stem cells offer great potential for addressing AMD.
Stem Cell Treatment for Retinitis Pigmentosa:
Retinitis pigmentosa (RP) encompasses a group of inherited conditions that cause progressive retinal degeneration resulting in vision loss, especially at night. Current treatment options include vitamin and nutritional supplementation and experimental therapies including gene therapy, retinal cell transplantation, and retinal prosthesis. Stem cells offer a minimally invasive investigational alternative.
Stem Cell Treatment for Optic Neuritis:
Optic Neuritis involves inflammatory, demyelination of the optic nerve, which may result in vision loss, eye pain, photopsias (flickering or flashing light), and/or loss of color vision. Standard treatment uses corticosteroids to reduce inflammation. Stem cell therapy addresses the cause of optic neuritis instead of solely reducing inflammation.
Stem Cell Treatment for Glaucoma:
Glaucoma is characterized by elevated intraocular pressure, which leads to optic nerve damage, progressive visual field loss and ultimately, irreversible blindness if left untreated. Current therapies include prescription drugs, laser therapy, and surgery. Stem cells offer the hope of mitigating the loss of vision.
Making History at the San Francisco Stem Cell Treatment Center
Together, Dr. Ahvie Herskowitz and Dr. David Milstein made history performing the first SJS (Stevens-Johnson Syndrome) stem cell ophthalmic injection on 7-9-15 at the San Francisco Stem Cell Treatment Center!
Stem Cell Treatment for Stevens-Johnson Syndrome (SJS)
Stevens-Johnson syndrome (SJS) is a form of toxic epidermal necrolysis (TEN), which is a life-threatening skin condition where cell death causes the skin layers of the epidermis to separate from the dermis. This syndrome is considered to be a hypersensitivity complex that affects the skin and mucous membranes, and can be caused by certain medications, infections or more rarely cancers. SJS can affect the ocular components resulting in conjunctival infection, sloughing of skin, erythematous macules and patches, and symblepharon formation may occur with severe pseudomembranous conjunctivitis. Primary corneal and iritis involvement are rare. Later complications may occur to include structural anomalies of the eyelid, (ectropion and entropion) and Trichiasis. Damage to tear and oil glands can develop and lead to dry eyes with lack of tear production necessary for the health of the ocular surface.
Here at the San Francisco Stem Cell Treatment Center, we have treated SJS patients with autologous intravenous and intraocular stem cells with very promising improvements – please see patient testimonial and video below.
Update from Sofia now 9 months post stem cell procedure eye injections:
“I can be almost all day without remembering that I have eyes, because I am not feeling them, and that is a great sensation! Before the procedure, I only had one wish: spend the day without feeling my eyes and that was achieved.”
Update from Sofia, 6 months post stem cell procedure eye injections:
“I am doing very well. This month was the best moth since I had SJS in 2007. I have no inflammation, I feel my eyes more comfortable, and they are producing less mucous. I went to see my doctor a few days ago and she was really happy with my results.”
61 year old with history of Stevens-Johnsons Syndrome and COPD
Now 4 days after his stem cell procedure, he reports 90% reduction in eye pain and increased visual acuity, less requirements for eye drops, and less coughing!
Read more patient testimonials
SJS Stem Cell Treatment
Rob recently had stem cell treatment at The San Francisco Stem Cell Treatment Center for a very serious cornea situation (to put it mildly). Dr. Ahvie Herskowitz is breaking down SJS barriers with the application of stem cells over amniotic membrane. Rob was brave enough to be the first, hopefully not the last. One month post procedure, Rob’s doc (who is well respected in stem cell / cornea circles) says that the cornea is fully healed and has never seen Rob’s eyes look so good. This is beyond huge news for our world of SJS.
Visual Improvement Following Ozone Therapy in Dry Age Related Macular Degeneration
The dry form of ARMD is becoming a serious problem because of the rise in the number of old individuals. No effective therapy is available in dry ARMD except for the illusory oral administration of antioxidant vitamins. Despite scepticism in the medical community, the therapeutic effect of ozone therapy had been evaluated since 1996.
Read more related articles
Cured blind man, U.S. senator crusade on Capitol Hill for stem cell innovations
Mesenchymal Stem/Stromal Cells Protect the Ocular Surface by Suppressing Inflammation in an Experimental Dry Eye
So. Cal. Mom Losing Eyesight Has Stem Cell Procedure
Stem Cell Therapy May Someday Replace Corneal Transplants
Mesenchymal Stromal Cells Treatment Attenuates Dry Eye in Patients With Chronic Graft-versus-host Disease
Cell therapy is a promising approach for the treatment of refractory ocular disease.
Differentiation of mesenchymal stem cell in the microenviroment of retinitis pigments
In the ongoing discussion of using stem cells for cell replacement strategies, the most promising group of stem cells are those isolated from the adult organism.
Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration
Because there is no effective treatment for this retinal degeneration, potential application of cell-based therapy has attracted considerable attention.
Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome Model
The current study was set out to address the therapeutic efficacy of topically applied mesenchymal stem cells (MSCs) on dry eye syndrome (DES) induced by benzalkonium chloride (BAC) in rats.